EGFR and lung adenocarcinoma: USP22 is shown to regulate EGFR endocytosis through deubiquitination, resulting in sustained activation of the EGFR-dependent signaling pathway and promoting resistance to EGFR-TKIs in EGFR-mutated lung adenocarcinoma [88].